JP2015000064A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015000064A5 JP2015000064A5 JP2014123573A JP2014123573A JP2015000064A5 JP 2015000064 A5 JP2015000064 A5 JP 2015000064A5 JP 2014123573 A JP2014123573 A JP 2014123573A JP 2014123573 A JP2014123573 A JP 2014123573A JP 2015000064 A5 JP2015000064 A5 JP 2015000064A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- hematopoietic stem
- bone marrow
- progenitor cells
- primary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 17
- 238000000034 method Methods 0.000 claims 13
- 208000018240 Bone Marrow Failure disease Diseases 0.000 claims 7
- 208000014905 bone marrow failure syndrome Diseases 0.000 claims 7
- 108091034117 Oligonucleotide Proteins 0.000 claims 6
- 210000000130 stem cell Anatomy 0.000 claims 5
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000004700 fetal blood Anatomy 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/919,241 US9428748B2 (en) | 2013-06-17 | 2013-06-17 | Method of expanding hematopoietic stem cells |
| US13/919,241 | 2013-06-17 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015000064A JP2015000064A (ja) | 2015-01-05 |
| JP2015000064A5 true JP2015000064A5 (enExample) | 2017-08-03 |
| JP6532653B2 JP6532653B2 (ja) | 2019-06-19 |
Family
ID=50942591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014123573A Active JP6532653B2 (ja) | 2013-06-17 | 2014-06-16 | 造血幹細胞の増殖方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9428748B2 (enExample) |
| EP (1) | EP2816107B1 (enExample) |
| JP (1) | JP6532653B2 (enExample) |
| DK (1) | DK2816107T3 (enExample) |
| ES (1) | ES2757508T3 (enExample) |
| HU (1) | HUE046356T2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180109985A (ko) * | 2016-02-04 | 2018-10-08 | 젱룬 주 | 염증성 질환의 치료 및 진단 |
| GB201608944D0 (en) * | 2016-05-20 | 2016-07-06 | Ospedale San Raffaele And Fond Telethon | Gene Tharapy |
| JP2023525510A (ja) | 2020-05-06 | 2023-06-16 | セレクティス ソシエテ アノニム | 治療用タンパク質の送達のために細胞を遺伝子改変する方法 |
| JP7750865B2 (ja) | 2020-05-06 | 2025-10-07 | セレクティス ソシエテ アノニム | 細胞ゲノムにおける外因性配列の標的化挿入のための方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| JPS63501765A (ja) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途 |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5908779A (en) | 1993-12-01 | 1999-06-01 | University Of Connecticut | Targeted RNA degradation using nuclear antisense RNA |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| EP1224261A1 (en) * | 1999-10-07 | 2002-07-24 | Avi Biopharma, Inc. | C-myc antisense-treated hematopoietic stem cell composition and method |
| AU2004215097A1 (en) * | 2003-02-10 | 2004-09-10 | National Institute Of Advanced Industrial Science And Technology | Regulation of gene expression by DNA interference |
| AU2004217699B2 (en) * | 2003-03-07 | 2008-07-03 | Gamida-Cell Ltd. | Expansion of renewable stem cell populations using modulators of PI 3-kinase |
| EP1991246B1 (en) | 2006-02-22 | 2013-09-11 | Zhenglun Zhu | Treatment of development-related disorders |
| AU2007230902B2 (en) * | 2006-03-24 | 2013-03-14 | Children's Medical Center Corporation | Method to modulate hematopoietic stem cell growth |
| HUE042736T2 (hu) * | 2009-07-15 | 2019-07-29 | Zhenglun Zhu | Gyulladásos vagy autoimmun rendellenességek kezelésének irányítása HOM-1 kifejezés alkalmazásával |
| WO2011028819A1 (en) * | 2009-09-01 | 2011-03-10 | The Trustees Of Columbia University In The City Of New York | Synergistic transcription modules and uses thereof |
| CN103415615B (zh) | 2010-11-24 | 2015-11-25 | 高红 | 扩增造血干细胞 |
| WO2012170979A1 (en) | 2011-06-10 | 2012-12-13 | Zhenglun Zhu | Human homeobox gene ventx and macrophage terminal differentiation and activation, compositions and methods thereof |
| CN104024854A (zh) * | 2011-09-11 | 2014-09-03 | 奥拉森斯有限责任公司 | 细胞摄取对照系统 |
| JP6559117B2 (ja) * | 2013-04-10 | 2019-08-14 | ツェンルン チュー | ヒト樹状細胞の分化および成熟を調節するホメオボックス転写因子ＶｅｎｔＸ |
-
2013
- 2013-06-17 US US13/919,241 patent/US9428748B2/en active Active
-
2014
- 2014-06-16 JP JP2014123573A patent/JP6532653B2/ja active Active
- 2014-06-16 DK DK14172624T patent/DK2816107T3/da active
- 2014-06-16 HU HUE14172624A patent/HUE046356T2/hu unknown
- 2014-06-16 EP EP14172624.0A patent/EP2816107B1/en active Active
- 2014-06-16 ES ES14172624T patent/ES2757508T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022006107A (es) | Metodos y composiciones para dosificacion en terapia celular adoptiva. | |
| MX384315B (es) | Agente para el tratamiento y/o prevención de enfermedades asociadas con anormalidades inmunes. | |
| BR112017014269A2 (pt) | células exterminadoras naturais e usos das mesmas | |
| MX363243B (es) | Composiciones para tratar cáncer y usos de dichas composiciones. | |
| JP2014240404A5 (enExample) | ||
| TW201613956A (en) | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) | |
| MX2016001587A (es) | Inhibidores de kdm1a para el tratamiento de enfermedades. | |
| NZ739448A (en) | Transgene genetic tags and methods of use | |
| JP2014169326A5 (enExample) | ||
| MA40057A (fr) | Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants | |
| PH12016502447B1 (en) | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo | |
| JP2018522041A5 (enExample) | ||
| HRP20240798T1 (hr) | Terapija matičnim stanicama kod patologija endometrija | |
| JP2015000064A5 (enExample) | ||
| EA201790563A8 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
| BR112018074941A2 (pt) | combinações farmacêuticas | |
| WO2014152754A3 (en) | Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens | |
| BR112018008931A8 (pt) | ?compostos para tratamento de distúrbios hipoproliferativos? | |
| PH12016502243A1 (en) | Pharmaceutical compositions for treating infectious diseases | |
| RU2016108808A (ru) | Терапевтическое применение vegf-c и ccbe1 | |
| AR095076A1 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| JP2015518835A5 (enExample) | ||
| CY1122042T1 (el) | Συνθεση για χρηση στη θεραπεια του πονου που σχετιζεται με μεσοσπονδυλιο δισκο | |
| JP2015044878A5 (enExample) | ||
| JP2016515123A5 (enExample) |